Viragen, Inc. today announced that it has entered into a license agreement with
Kuhnil Pharm Co. Ltd., headquartered in Seoul, to distribute Multiferon(R) (multi-subtype,
natural human alpha interferon) in South Korea. While financial terms were not
disclosed, Viragen will receive a small up-front license fee in exchange for
providing exclusive marketing rights to the drug in South Korea for a period
of ten years.